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Several of the recently described leucocyte surface (glyco)-proteins with significant amino acid sequence similarity (human CD9, CD37. CD53. 
CD63, TAPA-1, CO-029 and R2 and several homologues of other species) are distinguished by the polypeptide chain apparently four times crossing 
the membrane. Although the biological role of none of these molecules is known, their structure, associations with other membrane components 
and the effects of specific monoclonal antibodies uggest that they may constitute a family of ion channels or other transport molecules. 
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Surface molecules of leucocytes, the cells of the im- 
mune system, are currently the subject of intense 
research because of their great theoretical and practical 
importance. So far more than 100 of structurally well- 
characterized human leucocyte surface proteins, 
glycoproteins and glycolipids have been described and 
many of them have been assigned biological functions 
(for review see [ 11). Recent rapid prcjgress in this field is 
mainly due to the USC of monoclonal antibodies (mAbs) 
and modern cDNA cloning methods but also the result 
of the regular organization of International Workshops 
on Human Leucocyte Differentiation Antigens. The 
Workshop conferences define ‘novel’ leucocyte surface 
molecules (‘antigens’) on the basis of broad comparitive 
mAb-based studies and assign them official names of 
the CD-system (CD stands for ‘cluster of differentia- 
tion’ and denotes originally a cluster of monoclonal an- 
tibodies that were found during these workshop studies 
to react similarly in various tests, ultimately therefore 
recognizing a common cell-surface antigen). So far 
there are CD1 to CD78, some of them actually being 
groups of several closely related molecular species (e.g. 
CDla, b, c, or CD45RA, RB, RC, RO). Several tens of 
other well-defined molecules are still waiting for their 
CD-names. It seems likely that many if not most other 
molecules expressed on the surface of various types of 
leucocytes are ‘yet to be discovered. 
Several frmctionally distinct groups of these 
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molecules can be clearly delineated such as antigen- 
specific receptors, cytokine receptors, several types of’ 
adhesion molecules, complement receptors and 
complement-regulatory proteins, Fc-receptors, surface 
enzymes, transport proteins, etc. Individual members 
of these functional groups are often also structuraiiy 
related and thus constitute structural families such as 
the immunoglobulins, cytokine receptors, complement 
receptors, integrins and membrane lectins [ 11. 
Recently, several of the newly cloned surface 
(g1yco)proteins have been found to be structurally 
closely related and thus constituting a novel family 
(Tables I and II). A characteristic feature of all these 
molecules is the polypeptide chain containing four 
hydrophobic, presumably membrane-spanning seg- 
ments and a single major presumably extracellular and 
usually N-glycosylated loop (Fig. 1). It seems very likely 
that both the NHz- and COOH-termini are localized 
intracellularly [4]. The highest degree of sequence 
similarity between the members of this new family is 
observed within the putative transmembrane regions. 
Among other highly conserved residues are six cysteine 
residues (positions 71, 80, 144, 145, 161 and 170 in 
CD53) and some of the amino acids flanking them (Fig. 
1). It is not known how many of these (and other) cys- 
teines are involved in cystine bridges, presumably 
stabilizing the structure of these molecules. Several 
short sequence motifs appear to be strikingly conserved 
71 80 .145 170 
such as the GCXGXXXEXXC, CCG, or EGC 
(numbering taken from CD53). These highly conserved 
seqttences could perhaps give. some clues about the 
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Table 1 
Properties of the CD9KD37KD53KD63 family members 
August I991 
Expression MoJ.wt. 
Wa) 
Polypeptide 
chain length 
(amino acid residues) 
Comments 
CD9 [2] thrombocytes, 
(human) pre-B cells 
CD37 
[3*41 
(human) 
B cells (strongly) 
other leucocytes 
(weakly) 
CD53 
[6,71 
(human) 
leucocytes 32-40 219 CDS3 appears to be the best pan-leucocyte marker 
CD63/ME49f 
f%9] 
(human) 
very broad 
intracellularly 
TAPA-I 
IlO.lll 
[human] 
broad 26 236 
R2 [12] 
(human) 
mRNA strongly 
upregulated in 
activated cells 
co-029 [13] 
(human) 
some carcinoma 
cell lines 
rat CD37 
151 
ox-44 leucocytes 
14,141 (except for CD4 + 8 + 
(rat) (thymacytes) 
Sm23 [I51 
(Schisoslomo 
munsoni) 
s5.7 
(human) 
bros.d 
24 227 
40-50 281 intracellularly present in vesicle-like structures !3]; 
the origin31 sequence [4] was revised and the 
C-terminus corrected [5] 
30-60 228 primarily localized in lysosomal membranes [21]; 
cell surface expression can be induced by various 
types of activation and on some tumour cells 
mAb ha:j reversible antiproliferative effects [JO]; 
associated with several other components including 
Leul3 (I 11; probably not glycosylated 
protein 
undescribed 
267 cDNA cloned and sequenced; protein product 
so far undescribed 
27-34 237 
protein 
undescribed 
40-50 
281 
219 
cDN/i cloned and sequenced; protein product 
so far undescribed 
rat CDS3 homologue 
23 218 probably not glycosylated 
so far unpublished paper by 1. Stamenkovic 
and G. Rovera cited in [7] 
Table 11 
Degree of sequence similarity between the members of the family” 
- 
CD37 CD53 CD63 R2 TAPA- 1 CO-029 rat CD37 ox-44 Sm23 
(ME491) (rat CD53) -- 
CD29 2c 24 25 24 45 36 22 26 21 
CD37 33 22 34 21 22. 80 33 20 
CD53 31 33 21 26 34 81 28 
CD63 25 20 26 22 34 36 
82 23 28 34 32 25 
TAP A- l 33 20 27 20 
co-029 22 25 26 
rat CD37 34 21 
ox-44 28 
’ Given in % of amino acid residues that are identicaJ_at he corresponding positions in the sequence of the two compared molecules. The match 
was optimized by introducing appropriate deletions into the compared sequences; the positions with a deletion in one of the partners were not 
taken into account. The mo!ecules are actually much more similar, as many of the non-identities are conservative replacements. 
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Fig. 1. Schematic representation of the CD53 polypeptide chain and 
degree of sequence similarity to other members of the family. Thick 
line represents the hydrophobic, presumably membrane-spanning 
regions. The membrane and the orientation of the polypeptide chain 
therein is also schematically shown. iBoth polypeptide chain ends are 
presumably located intracellularly, while the major N-glycosylated 
loop is extracellular. The positions in which four or five (O), six or 
seven (@o) and all eight (@@o) fully sequenced family members 
(CD9. CD37, CD53, CD63, TAPA-I, R2, CO-029 and Sm23) are 
identical; rat CD37 and OX-44 (rat CD53) were excluded because of 
their close similarity to the human homologues. Arrows indicate the 
positions of conserved cysteines, double arrows indicate approximate 
positions of major sites where in some of the family members addi- 
tional stretches of amino acids are inserted. The sites of N- 
glycosylation are indicated (CHO). 
functionally important regions of these molecules. On 
the other hand, there are relatively large differences in 
the sizes of the putative major extracellular loops (ap- 
prox. 125 amino acids in CD37 vs approx. 80 residues 
in CD9, CD53, TAPA-! and Sm23). Most of these 
molecules are heavily ZV-glycosylated in the putative ex- 
tracellular loop, while TAP&I and Sm23 seem to lack 
any carbohydrate moiety [10,15]. At least CD9 and 
TAPA- have been shown to be covalently modified by 
acylation [ 10,161. 
Several other membrane proteins exist whose 
organization is roughly similar, i.e. their polypeptide 
chains presumably cross the membrane four times. One 
of them is the P-subunit of the high-affinity IgE recep- 
tor [17]. The others are several neuronal amino acid 
receptors (but in this case both ends of the polypeptide 
chain are localized extracellularly [IS]). None of these 
proteins share any significant sequence similarity to the 
CD9/CD37/CD53/CD63 family. 
Individual members of this family widely differ in 
their expression (Table I): while CD9 and CD37 are pre- 
sent in very specific cell types only, CD53 is expressed 
in. all leucocytes (but not in other cells) and CD63 
(ME491) is a ubiquitous molecule. R2 seems to be 
remarkably up-regulated in activated T lymphocytes 
u21. 
Biological functions of these molecules are unknown, 
but functional effects of some specific mAbs may pro- 
vide clues in this respect. MAbs may either mimic the 
effects of natural ligands of putative recept.ors, block 
them or induce conformational changes modifying e.g. 
functions of transport molecules. However, the results 
of such experiments must al*;;ayys be juciged with some 
caution as crosslinking of cell surface molecules with 
bivalent or multivalent antibodies may in some cases in- 
duce artificia1 effects unrelated to their true biological 
role. An ant-CD37 mAb has been shown to modulate 
activation of I3 lymphocytes [19]. Addition of an mAb 
against CD53 to monocytes followed by crosslinking 
with polyclonal antibodies against mouse im- 
munoglobulin elicits strong oxidative burst response in 
these cells (V. BaZil and V. HoPejSi, unpublished). An 
mAb against he TAPA-I antigen strongly reversibly in- 
hibits proliferation of some lymphoma cell lines [lo]. 
MAbs against he CD9 antigen induce homotypic adhe- 
sion (aggregation) of pre-B cell lines [20] and throm- 
bocytes [21] and calcium influx in these cells [22]. The 
mAb-induced aggregation of thrombocytes i  depend- 
ent on co-crosslinking of CD9 and thrombocyte Fc y- 
receptor II (CDw32) and is associated with full activa- 
tion of these cells [23]. 
Very interesting is the ME491 antigen which has been 
recently found to be identical to CID63 [24]. 
ME491KD63 is one of the major components of 
lysosome membranes; it was suggested that due to its 
extremely heavy glycosylation it may be highly resistant 
to lysosomal enzymes and thus may be one of the 
glycoproteins protecting and stabilizing the lysosomal 
membrane [24] (interestingly, the CD37 antigen is also 
strongly expressed in so far uncharacterized in- 
tracellular vesicle-like structures [3]). Expression of this 
molecule on the cell surface may be a consequence of
the fusion of lysosomal membranes with the plasma 
membrane in some activated cells. However, other 
observations may indicate that the cell surface 
ME491KD63 molecules do have a functional role: the 
J W7 mAb markedly inhibited phorbolester-induced 
monocyte adherence to serum-coated surfaces and ag- 
gregation of T and B lymphocytes and U937 cells [25]. 
The ME491 antibody was reported to be internalized 
after binding to the surface of melanoma and car- 
cinoma cells; inside the cells it was bound to a 55 kDa 
chromatin protein and markedly inhibited transcription 
of ribosomal RNA genes [26]. The relationship of the 
chromatin protein to the ME491 antigen is unclear. 
Nuclear uptake of the antibody was stimulated after 
preincubation of cells with puromycin or actinomycin 
D 1261. It is quite unclear whether and how this 
remarkable phenomenon is related to the biological 
function of ME491KD63. In addition, an mAb against 
rat homologue of CD631ME491 inhibited IgE- 
mediated histamine release from basophilic leukaemia 
cells [27]. 
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The existence of a member of this family, the Sm23 
antigen, in the phylogenetically very distant in- 
vertebrate species Schisostoma mansoni may indicate 
that these proteins are evolutionarily very old and serve 
some essential function(s). On the other hand, the an- 
tigenic similarity between the parasite molecule and 
multipIe Ieucocyte surface mol,cc!1tea might nlav an as 
yet undetermined role in combating the host im.nune 
system (121. 
Some of the above described effects h..&?ted by the 
binding of antibodies to these cell surface molecules 
may be related to the reported non-covalent associa- 
tions of some of them with other cell surface com- 
ponents: the CD9 antigen may be associated on the 
thrombocyte surface with the major adhesive molecule 
of these cells, the integrin gp IIb/IIIa [28]. It was even 
claimed that CD9 has a k.inase activity [29]. The 
TAPA-I protein is associated on some cell lines with 
several other molecules, incl.uding the 16 kDa Leu-13 
antigen of so far unknown function 111). Especially in- 
teresting is the recent report on apparent association of 
rat homologue of the ME491 (CD63) antigen with the 
high affinity IgE receptor [27]. 
The structure of this family of membrane (glyco)pro- 
teins (polypeptide chain multiply crossing the mem- 
brane) is reminiscent of many well known ion channels 
and other transport molecules [30-323 and also of some 
receptors [ 18,33,34]. The observed functional effects of 
some mAbs against hese molecules eem to be compati- 
ble with a similar role. With respect o the reported 
associations with other cell surface components it is 
tempting to suggest that these molecules could serve as 
receptor-linked ion channels. Future experiments are 
needed to test such a hypothesis. 
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